In its first-quarter 2025 investor letter, Carillon Eagle Mid Cap Growth Fund highlighted stocks such as Cencora, Inc. (NYSE:COR). Cencora, Inc. (NYSE:COR) is a pharmaceutical products distributor.

In its first-quarter 2025 investor letter, Carillon Eagle Mid Cap Growth Fund highlighted stocks such as Cencora, Inc. (NYSE:COR). Cencora, Inc. (NYSE:COR) is a pharmaceutical products distributor.

Shares of Cencora Inc. COR rallied 1.24% to $285.90 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.74% to 5,525.21 and the ...

Has Cencora (COR) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Cencora is a member of our Medical group, which includes 1002 ...

Citi analyst Daniel Grosslight maintained a Buy rating on Cencora (COR – Research Report) today and set a price target of $330.00. The ...

Morgan Stanley analyst Erin Wright raised the firm’s price target on Cencora (COR) to $288 from $263 and keeps an Equal Weight rating on the shares. While policy will be “front and center ...

Cencora, Inc. (NYSE:COR – Free Report) – Stock analysts at Leerink Partnrs raised their FY2028 EPS estimates for shares of Cencora in a note issued to investors on Wednesday, April 2nd.

Cencora COR has outperformed the market over the past 5 years by 12.25% on an annualized basis producing an average annual return of 25.82%. Currently, Cencora has a market capitalization of $55. ...